Propiverine

Prevalence of Overactive Bladder, its Under-Diagnosis, and Risk Factors in a Male Urologic Veterans Population

(2012) Wellman W Cheung et al.   International Journal of Medical Sciences

An Overview on Mixed Action Drugs for the Treatment of Overactive Bladder and Detrusor Overactivity

(2012) A.D. Asimakopoulos et al.   UROLOGIA INTERNATIONALIS

Determination of propiverine hydrochloride in human plasma by high performance liquid chromatographytandem mass spectrometry: application to the pharmacokinetic study of a sustained release formulation

(2011) Huang Meihua et al.   ARZNEIMITTEL-FORSCHUNG-DRUG RESEARCH

The influence of propiverine hydrochloride on cardiac repolarization in healthy women and cardiac male patients

(2011) F. Donath et al.   INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS

Propiverine hydrochloride in Japanese patients with overactive bladder: A randomized, double-blind, placebo-controlled trial

(2011) Momokazu Gotoh et al.   INTERNATIONAL JOURNAL OF UROLOGY

Influence of a Fat-Rich Meal on Bioavailability of Extended-Release and Immediate-Release Propiverine

(2011) Werner Siegmund et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Systematic Review and Meta-Analysis: Do Clinical Trials Testing Antimuscarinic Agents for Overactive Bladder Adequately Measure Central Nervous System Adverse Events?

(2011) Amélie Paquette et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Efficacy of propiverine ER with or without α-blockers related to maximum urinary flow rate in adult men with OAB: results of a 12-week, multicenter, non-interventional study

(2011) Matthias Oelke et al.   WORLD JOURNAL OF UROLOGY

The muscarinic receptor antagonist propiverine exhibits α1-adrenoceptor antagonism in human prostate and porcine trigonum

(2011) Melinda Wuest et al.   WORLD JOURNAL OF UROLOGY

Urodynamic effects of propiverine in children and adolescents with neurogenic bladder: Results of a prospective long-term study

(2011) Heinrich Schulte-Baukloh et al.   Journal of Pediatric Urology

The cost-effectiveness of solifenacin vs fesoterodine, oxybutynin immediate-release, propiverine, tolterodine extended-release and tolterodine immediate-release in the treatment of patients with overactive bladder in the UK National Health Service

(2010) Linda Cardozo et al.   BJU INTERNATIONAL

Pharmacokinetics and Pharmacodynamics of Propiverine in Children Aged between 5 and 10 Years with Symptoms of Overactive Bladder

(2010) Werner Siegmund et al.   CLINICAL PHARMACOKINETICS

New strategies for medical management of overactive bladder in children

(2010) Annette Schröder et al.   CURRENT OPINION IN UROLOGY

Anticholinergic effects of cis- and trans-isomers of two metabolites of propiverine

(2010) Stefan Propping et al.   NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY

Propiverine vs oxybutynin for treating neurogenic detrusor overactivity in children and adolescents: results of a multicentre observational cohort study

(2009) Helmut Madersbacher et al.   BJU INTERNATIONAL

Urinary urgency outcomes after propiverine treatment for an overactive bladder: the ‘Propiverine study on overactive bladder including urgency data’

(2009) Kyu-Sung Lee et al.   BJU INTERNATIONAL

Efficacy, tolerability and safety of propiverine hydrochloride in comparison to oxybutynin in children with urge incontinence due to overactive bladder: Results of a multicentre observational cohort study

(2009) Schahnaz Alloussi et al.   BJU INTERNATIONAL

EAU Guidelines on Neurogenic Lower Urinary Tract Dysfunction

(2009) Manfred Stöhrer et al.   EUROPEAN UROLOGY

Clinical guidelines for overactive bladder

(2009) Osamu Yamaguchi et al.   INTERNATIONAL JOURNAL OF UROLOGY

A randomized, double-blind, placebo- and propiverine-controlled trial of the novel antimuscarinic agent imidafenacin in Japanese patients with overactive bladder

(2009) Yukio Homma et al.   INTERNATIONAL JOURNAL OF UROLOGY

HOW TO MANAGE OVERACTIVE BLADDER IN ELDERLY INDIVIDUALS WITH DEMENTIA? A COMBINED USE OF DONEPEZIL, A CENTRAL ACETYLCHOLINESTERASE INHIBITOR, AND PROPIVERINE, A PERIPHERAL MUSCARINE RECEPTOR ANTAGONIST

(2009) Ryuji Sakakibara et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Naftopidil and propiverine hydrochloride for treatment of male lower urinary tract symptoms suggestive of benign prostatic hyperplasia and concomitant overactive bladder: A prospective randomized controlled study

(2009) Teruhiko Yokoyama et al.   SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY

Therapie der überaktiven Blase mit Propiverin ER

(2009) P.L. Kessler-Zumpe et al.   UROLOGE

Oral absorption of propiverine solution and of the immediate and extended release dosage forms: influence of regioselective intestinal elimination

(2008) Karen May et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Age and Bladder Outlet Obstruction Are Independently Associated with Detrusor Overactivity in Patients with Benign Prostatic Hyperplasia

(2008) Matthias Oelke et al.   EUROPEAN UROLOGY

The Effects of Antimuscarinic Treatments in Overactive Bladder: An Update of a Systematic Review and Meta-Analysis

(2008) Christopher R. Chapple et al.   EUROPEAN UROLOGY

Treatment with Propiverine in Children Suffering from Nonneurogenic Overactive Bladder and Urinary Incontinence: Results of a Randomized Placebo-Controlled Phase 3 Clinical Trial

(2008) Daniela Marschall-Kehrel et al.   EUROPEAN UROLOGY

Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian-Time Rhythms

(2008) Karen May et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Prevalence and Associated Factors of Overactive Bladder in Korean Children 5-13 Years Old: A Nationwide Multicenter Study

(2008) Jae Min Chung et al.   UROLOGY